SEC Form 4 · accession 0001209191-15-075199

Aclaris Therapeutics, Inc. · ACRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 13, 2015

Accepted (ET)

Oct 13, 2015 · 1:30 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001557746

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Oct 13, 2015	C	3,433,646	—	A	3,736,852	I	By funds
Common Stock^F3	Oct 13, 2015	P	454,545	$11.00	A	4,191,397	I	By funds

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F3,F2	—	Oct 13, 2015	C	8,652,500	D	—	—	Common Stock	2,507,970	I
Series B Preferred Stock^F3,F2	—	Oct 13, 2015	C	1,818,182	D	—	—	Common Stock	527,009	I
Series C Preferred Stock^F3,F2	—	Oct 13, 2015	C	1,375,405	D	—	—	Common Stock	398,667	I

F1The total represents shares received upon conversion of shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock.
F2Effective upon the closing of the issuer's initial public offering of its common stock, each share of preferred stock automatically converted into 0.289855 shares of common stock. The preferred stock had no expiration date.
F3The reporting person is one of the managing members of Vivo Ventures VII, LLC ("VV LLC"), which is the general partner of each of Vivo Ventures Fund VII, L.P. ("VVF") and Vivo Ventures VII Affiliates Fund, L.P. ("VVAF"), the record holders of the securities, and may be deemed to share voting and dispositive power over the securities held by VVF and VVAF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.